Suven Life Sciences Limited (SUVEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Suven Life Sciences Limited (SUVEN) has a cash flow conversion efficiency ratio of -0.368x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-1.03 Billion ≈ $-11.18 Million USD) by net assets (Rs2.81 Billion ≈ $30.42 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Suven Life Sciences Limited (SUVEN) defensive interval to measure how many days the company can operate on defensive assets alone.
Suven Life Sciences Limited - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Suven Life Sciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Suven Life Sciences Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Suven Life Sciences Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hangzhou Gaoxin Rubber & Plastic Materials Co Ltd
SHE:300478
|
-0.422x |
|
Global Top E Commerce Co Ltd
SHE:002640
|
-0.326x |
|
Tianma Bearing Group Co Ltd
SHE:002122
|
0.003x |
|
Sgis Songshan Co Ltd
SHE:000717
|
0.093x |
|
Golden Entertainment Inc
NASDAQ:GDEN
|
0.062x |
|
SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
NASDAQ:HDL
|
0.087x |
|
UBISOFT ENTMT ADR 1/5
F:UEN0
|
N/A |
|
Sirio Pharma
SHE:300791
|
0.038x |
Annual Cash Flow Conversion Efficiency for Suven Life Sciences Limited (2005–2025)
The table below shows the annual cash flow conversion efficiency of Suven Life Sciences Limited from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see SUVEN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs1.10 Billion ≈ $11.89 Million |
Rs-1.48 Billion ≈ $-16.06 Million |
-1.350x | -215.69% |
| 2024-03-31 | Rs2.70 Billion ≈ $29.20 Million |
Rs-1.15 Billion ≈ $-12.49 Million |
-0.428x | -55.59% |
| 2023-03-31 | Rs3.75 Billion ≈ $40.59 Million |
Rs-1.03 Billion ≈ $-11.16 Million |
-0.275x | +79.28% |
| 2022-03-31 | Rs961.45 Million ≈ $10.40 Million |
Rs-1.28 Billion ≈ $-13.79 Million |
-1.327x | -49.20% |
| 2021-03-31 | Rs1.08 Billion ≈ $11.68 Million |
Rs-960.24 Million ≈ $-10.38 Million |
-0.889x | +34.25% |
| 2020-03-31 | Rs1.43 Billion ≈ $15.50 Million |
Rs-1.94 Billion ≈ $-20.96 Million |
-1.352x | -3261.03% |
| 2019-03-31 | Rs8.31 Billion ≈ $89.87 Million |
Rs355.49 Million ≈ $3.84 Million |
0.043x | -53.06% |
| 2018-03-31 | Rs7.67 Billion ≈ $82.99 Million |
Rs699.36 Million ≈ $7.56 Million |
0.091x | -44.15% |
| 2017-03-31 | Rs6.67 Billion ≈ $72.13 Million |
Rs1.09 Billion ≈ $11.77 Million |
0.163x | +39.04% |
| 2016-03-31 | Rs5.95 Billion ≈ $64.40 Million |
Rs698.78 Million ≈ $7.56 Million |
0.117x | -54.10% |
| 2015-03-31 | Rs5.59 Billion ≈ $60.49 Million |
Rs1.43 Billion ≈ $15.46 Million |
0.256x | -44.27% |
| 2014-03-31 | Rs2.64 Billion ≈ $28.60 Million |
Rs1.21 Billion ≈ $13.12 Million |
0.459x | +130.90% |
| 2013-03-31 | Rs1.54 Billion ≈ $16.70 Million |
Rs306.86 Million ≈ $3.32 Million |
0.199x | -24.39% |
| 2012-03-31 | Rs1.28 Billion ≈ $13.79 Million |
Rs335.07 Million ≈ $3.62 Million |
0.263x | +503.70% |
| 2011-03-31 | Rs1.27 Billion ≈ $13.71 Million |
Rs55.16 Million ≈ $596.55K |
0.044x | -60.24% |
| 2010-03-31 | Rs1.18 Billion ≈ $12.77 Million |
Rs129.25 Million ≈ $1.40 Million |
0.109x | -63.45% |
| 2009-03-31 | Rs1.14 Billion ≈ $12.38 Million |
Rs342.73 Million ≈ $3.71 Million |
0.299x | +709.03% |
| 2008-03-31 | Rs1.06 Billion ≈ $11.51 Million |
Rs39.38 Million ≈ $425.92K |
0.037x | -76.86% |
| 2007-03-31 | Rs1.02 Billion ≈ $10.98 Million |
Rs162.41 Million ≈ $1.76 Million |
0.160x | +161.76% |
| 2006-03-31 | Rs902.12 Million ≈ $9.76 Million |
Rs55.13 Million ≈ $596.25K |
0.061x | +135.07% |
| 2005-03-31 | Rs811.85 Million ≈ $8.78 Million |
Rs21.11 Million ≈ $228.26K |
0.026x | -- |
About Suven Life Sciences Limited
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candida… Read more